한빛사
>
한빛사논문
한빛사논문
- 조회108
Rida FatimaRida Fatima
인제대학교
J. Cachexia Sarcopenia Muscle, Feb 2025, 16 (1) | https://doi.org/10.1002/jcsm.13707
C-Terminal Agrin Fragment as a Biomarker for Sarcopenia: A Systematic Review and Meta-Analysis
Rida Fatima1,2,3, Yonghoon Kim1,2,3, Suhyeon Baek1,2,3, Reema Priyanka Suram1,2,3, Sun-Joung Leigh An1,3,4, Yonggeun Hong1,2,3,5
1 Department of Rehabilitation Science, Graduate School of Inje University, Gimhae, South Korea
2 Biohealth Products Research Center (BPRC), Inje University, Gimhae, South Korea
3 Research Center for Aged-Life Redesign (RCAR), Inje University, Gimhae, South Korea
4 Department of Occupational Therapy, College of Healthcare Medical Science & Engineering, Inje University, Gimhae, South Korea
5 Department of Physical Therapy, College of Healthcare Medical Science & Engineering, Inje University, Gimhae, South Korea
Correspondence: Yonggeun Hong
1 Department of Rehabilitation Science, Graduate School of Inje University, Gimhae, South Korea
2 Biohealth Products Research Center (BPRC), Inje University, Gimhae, South Korea
3 Research Center for Aged-Life Redesign (RCAR), Inje University, Gimhae, South Korea
4 Department of Occupational Therapy, College of Healthcare Medical Science & Engineering, Inje University, Gimhae, South Korea
5 Department of Physical Therapy, College of Healthcare Medical Science & Engineering, Inje University, Gimhae, South Korea
Correspondence: Yonggeun Hong
Abstract
Background: Sarcopenia is a gradual decline in skeletal muscle mass and strength, which eventually leads to reduced physical performance. 50% of people aged 60-80 years suffer from sarcopenia. Considering the devastating outcomes and the importance of promoting healthy ageing, the diagnosis and prevention of sarcopenia is of utmost importance. Recently, C-terminal agrin fragment (CAF) has been identified as an indicator for early diagnosis of sarcopenia. So far, systematic reviews demonstrating CAF as a biomarker for sarcopenia have been conducted, but a meta-analysis is still needed. This study contains systematic review as well as detailed meta-analysis to better understand the association of CAF and sarcopenia.
Methods: Articles were primarily obtained from four different databases. Studies demonstrating the association between CAF and sarcopenia were selected. Data extraction and analysis were performed using STATASE 16 software. The risk of bias and quality assessment of each study was carried out using Joanna Briggs Institute (JBI) Critical Appraisal Tool. Meta-regression, subgroup and sensitivity analysis were conducted to identify the source of heterogeneity.
Results: Seventeen studies were included in the qualitative analysis, out of which 10 were included in the quantitative analysis. The meta-analysis showed that CAF levels were significantly higher in sarcopenia patients, with an effect size of 1.93 (ROM = 1.93, 95% CI [1.49 to 2.36]; p = 0.00) and 1.38 (ROM = 1.38, 95% CI [0.94 to 1.83], p = 0.00) when compared with non-sarcopenic and non-sarcopenic (other co-morbidities) group, respectively. CAF levels were also negatively associated with hand grip strength (HGS) and skeletal muscle index (SMI) with an effect size of 1.09 (ROM = 1.09 with 95% CI [1.05 to 1.13], p = 0.00) and 1.10 (ROM = 1.10 with 95% CI [1.05 to 1.14], p = 0.00), respectively. Meta-regression and subgroup analysis revealed that although sarcopenia is associated with increasing age, the correlation between CAF and age was statistically insignificant (p = 0.44), suggesting that the variation of age among sarcopenia patients could be source of heterogeneity among studies. All the studies included in the meta-analysis reported low risk of bias.
Conclusions: Our meta-analysis concluded that elevated CAF levels were associated with sarcopenia and decreased HGS and SMI. CAF could serve as a valuable marker for the early detection and monitoring of sarcopenia, ultimately facilitating the management and treatment of this debilitating condition.
Methods: Articles were primarily obtained from four different databases. Studies demonstrating the association between CAF and sarcopenia were selected. Data extraction and analysis were performed using STATASE 16 software. The risk of bias and quality assessment of each study was carried out using Joanna Briggs Institute (JBI) Critical Appraisal Tool. Meta-regression, subgroup and sensitivity analysis were conducted to identify the source of heterogeneity.
Results: Seventeen studies were included in the qualitative analysis, out of which 10 were included in the quantitative analysis. The meta-analysis showed that CAF levels were significantly higher in sarcopenia patients, with an effect size of 1.93 (ROM = 1.93, 95% CI [1.49 to 2.36]; p = 0.00) and 1.38 (ROM = 1.38, 95% CI [0.94 to 1.83], p = 0.00) when compared with non-sarcopenic and non-sarcopenic (other co-morbidities) group, respectively. CAF levels were also negatively associated with hand grip strength (HGS) and skeletal muscle index (SMI) with an effect size of 1.09 (ROM = 1.09 with 95% CI [1.05 to 1.13], p = 0.00) and 1.10 (ROM = 1.10 with 95% CI [1.05 to 1.14], p = 0.00), respectively. Meta-regression and subgroup analysis revealed that although sarcopenia is associated with increasing age, the correlation between CAF and age was statistically insignificant (p = 0.44), suggesting that the variation of age among sarcopenia patients could be source of heterogeneity among studies. All the studies included in the meta-analysis reported low risk of bias.
Conclusions: Our meta-analysis concluded that elevated CAF levels were associated with sarcopenia and decreased HGS and SMI. CAF could serve as a valuable marker for the early detection and monitoring of sarcopenia, ultimately facilitating the management and treatment of this debilitating condition.
논문정보
- Review Paper
- 2025년 02월 (BRIC 등록일 2025-02-03)
- 국내 연구진
- 바이오·의료융합 > 뇌인지과학
댓글 작성 로그인
팝업 닫기관련 링크
연구자 키워드
연구자 ID
관련분야 연구자보기
소속기관 논문보기
관련분야 논문보기
해당논문 저자보기
